文献速递消化系统肿瘤

肝细胞癌微血管侵犯患者边缘切除术后辅助立体定向体部放疗:一项随机对照试验

Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial.
PubMed 文献 · Eur J Cancer · 2022-03-15

这项单中心随机对照试验纳入76例微血管侵犯阳性且接受边缘切除的肝细胞癌患者,比较术后辅助立体定向体部放疗(SBRT)与单纯手术的疗效。SBRT组1、3、5年无病生存率分别为92.1%、65.8%、56.1%,单纯手术组分别为76.3%、36.8%、26.3%(p=0.005)。SBRT组总生存率有改善趋势但未达统计学显著(p=0.053),放疗相关不良事件总体发生率为31.6%,无3级及以上不良事件。

要点

  • 微血管侵犯阳性肝细胞癌边缘切除术后辅助SBRT可改善无病生存,5年无病生存率SBRT组56.1% vs 单纯手术组26.3%(p=0.005)。
  • 总生存率SBRT组有改善趋势但未达统计学显著,5年总生存率SBRT组75.0% vs 单纯手术组53.7%(p=0.053)。
  • 放疗相关不良事件总体发生率为31.6%(12/38),未发生3级及以上不良事件。

核心结论

  • 对微血管侵犯阳性且切缘不理想的肝细胞癌患者,术后对切除缘行SBRT是一种安全的辅助治疗方式,可预防局部复发并改善无病生存。

研究设计与样本

  • 单中心随机对照试验,在中国上海东方肝胆外科医院开展,纳入76例微血管侵犯阳性且接受边缘切除的肝细胞癌患者,随机分为术后辅助SBRT组与单纯手术组,每组38例。

主要发现

  • 1年、3年、5年无病生存率SBRT组分别为92.1%、65.8%、56.1%,单纯手术组分别为76.3%、36.8%、26.3%(p=0.005)。
  • 1年、3年、5年总生存率SBRT组分别为100%、89.5%、75.0%,单纯手术组分别为100.0%、68.4%、53.7%(p=0.053)。
  • SBRT单例总剂量为35 Gy,生物有效剂量(BED)为59.5 Gy。
  • 放疗相关不良事件总体发生率为31.6%(12/38),未发生3级及以上不良事件。

关键数值与推荐

  • SBRT采用CyberKnife®系统结合标记追踪装置,于术后一个月针对切除缘实施。
  • SBRT单例总剂量为35 Gy,生物有效剂量(BED)为59.5 Gy。
  • 试验注册号为NCT04891874。

临床怎么用

  • 作者认为,对微血管侵犯阳性且切缘不理想的肝细胞癌患者,术后对切除缘行SBRT是一种安全的辅助治疗方式,可预防局部复发并改善无病生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Marginal resection frequently occurred in hepatectomy for hepatocellular carcinoma (HCC), leading to increased local recurrence, especially among patients with microvascular invasion (MVI). Stereotactic body radiotherapy (SBRT) showed effectiveness in controlling tumour and tumour thrombosis. This study aimed to investigate the efficacy of SBRT, targeting on suboptimal resection margin, as adjuvant setting in MVI-positive HCC. METHODS: This was a single-centre randomised controlled trial conducted in Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Participants with MVI-positive HCC receiving marginal resection were randomly assigned to the postoperative adjuvant SBRT or surgery alone (SA) group. SBRT was delivered by the CyberKnife® system with marker tracking devices, targeting on resection margin one month after surgery. The disease-free survival (DFS) and overall survival (OS) were compared between the groups, and the adverse events (AEs) were monitored. This trial was registered on ClinicalTrials.gov, NCT04891874. FINDINGS: A total of 76 participants were enrolled, with 38 in each group. The one-, three-, and five-year DFS rates were 92.1%, 65.8%, and 56.1% in SBRT group versus 76.3%, 36.8%, and 26.3% in SA group, respectively (p = 0.005). The one-, three-, and five-year OS rates were 100%, 89.5%, and 75.0% in SBRT group versus 100.0%, 68.4%, and 53.7% in SA group, respectively (p = 0.053). The total dose of SBRT for single participant was 35 Gy, and the biological effective dose (BED) was 59.5 Gy. The overall incidence of radiotherapy-related AE was 31.6% (12/38), and no grade 3 or higher grade AE was developed. INTERPRETATION: SBRT on the resection margin provides a safe therapeutic modality of adjuvant setting in MVI-positive HCC with suboptimal resection margin. It prevents local recurrence and improves DFS. TRIAL REGISTRATION NUMBER: NCT04891874.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Shi C, Li Y, Geng L, et al. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. Eur J Cancer. 2022. PMID: 35303509. doi:10.1016/j.ejca.2022.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。